Progress in osteoprotegerin prevention and therapy for osteoporosis
Hou Jiaf
Abstract
Hou Jiaf
Abstract
Osteoprotegerin(OPG),receptor activator of NF-κB ligand(RANKL),receptor activator of NF-κB(RANK) are important factors in modulating bone resorption and formation.Osteoporosis is the result of many reasons that activate osteoclasts and destroy bone dynamic balance.OPG,which competes with RANK,binds with RANKL,inhibits osteoclast differentiation and activation and promotes osteoclast apoptosis.Recombinated OPG protein and OPG gene therapy are the most promising method that prevent and treat osteoporosis.The current status of recombination OPG protein and OPG gene therapy for osteoporosis was reviewed briefly in this article.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Osteoprotegerin(OPG),receptor activator of NF-κB ligand(RANKL),receptor activator of NF-κB(RANK) are important factors in modulating bone resorption and formation.Osteoporosis is the result of many reasons that activate osteoclasts and destroy bone dynamic balance.OPG,which competes with RANK,binds with RANKL,inhibits osteoclast differentiation and activation and promotes osteoclast apoptosis.Recombinated OPG protein and OPG gene therapy are the most promising method that prevent and treat osteoporosis.The current status of recombination OPG protein and OPG gene therapy for osteoporosis was reviewed briefly in this article.
Key concepts: Osteoprotegerin, RANKL, Osteoclast, Osteoporosis, Activator (genetics), Bone resorption, Medicine, Receptor